Phase III High Dose Interferon or Ipilimumab vs MK-3475(Pembrolizumab) in HighRisk Resected Melanoma

Trial ID or NCT#

NCT02506153

Status

not recruiting iconNOT RECRUITING

Purpose

This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Immunotherapy with monoclonal antibodies, such as ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether pembrolizumab is more effective than the current standard of care in treating patients with melanoma.

Official Title

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Manali Patel
Manali Patel
Medical oncologist
Associate Professor of Medicine (Oncology)
Zara M. Patel, MD
Zara M. Patel, MD
Head and neck surgeon, Otolaryngologist, Rhinologist, Smelling Disorders Specialist
Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurosurgery
Sunil Arani Reddy
Sunil Arani Reddy
Medical oncologist, Cutaneous oncology specialist
Clinical Associate Professor, Medicine - Oncology

Contact us to find out if this trial is right for you.

Contact

CCTO
650-198-7061

View on ClinicalTrials.gov